These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36114249)

  • 41. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.
    Nagler A; Labopin M; Huang XJ; Blaise D; Arcese W; Araujo MC; Socié G; Forcade E; Ciceri F; Canaani J; Giebel S; Brissot E; Caballer JS; Bazarbachi A; Yakoub-Agha I; Mohty M
    Bone Marrow Transplant; 2022 Apr; 57(4):572-578. PubMed ID: 35105964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
    Halaburda K; Labopin M; Houhou M; Niederwieser D; Finke J; Volin L; Maertens J; Cornelissen JJ; Milpied N; Stuhler G; Kröger N; Esteve J; Mohty M; Nagler A
    Bone Marrow Transplant; 2018 Jun; 53(6):683-691. PubMed ID: 29670208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
    Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
    Baron F; Nagler A; Galimard JE; Sanz J; Versluis J; Forcade E; Chevallier P; Sirvent A; Anthias C; Kuball J; Furst S; Rambaldi A; Sierra J; von dem Borne PA; Gallego Hernanz MP; Cluzeau T; Robinson S; Raiola AM; Labussière-Wallet H; Byrne JL; Malfuson JV; Ruggeri A; Mohty M; Ciceri F
    Br J Haematol; 2024 Jan; 204(1):250-259. PubMed ID: 37784256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.
    Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A
    J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
    Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
    Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
    Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
    Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Shimoni A; Niederwieser D; Mufti GJ; Zander AR; Arnold R; Greinix H; Cornelissen JJ; Jackson GH; Craddock C; Bunjes DW; Ganser A; Russell NH; Kyrcz-Krzemien S; Rocha V; Mohty M
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1422-9. PubMed ID: 22446014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
    Santoro N; Labopin M; Giannotti F; Ehninger G; Niederwieser D; Brecht A; Stelljes M; Kröger N; Einsele H; Eder M; Hallek M; Glass B; Finke J; Ciceri F; Mohty M; Ruggeri A; Nagler A
    J Hematol Oncol; 2018 Apr; 11(1):55. PubMed ID: 29661208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT.
    Nagler A; Galimard JE; Labopin M; Blaise D; Arcese W; Trisolini SM; Wu D; Pigneux A; Van Gorkom G; Rubio MT; Gedde-Dahl T; Huynh A; Lanza F; Gorin NC; Mohty M
    Cancer Med; 2023 Jan; 12(2):1482-1491. PubMed ID: 35891608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.
    Devillier R; Galimard JE; Labopin M; Blaise D; Raiola AM; Pavlu J; Castagna L; Socié G; Chalandon Y; Martino M; Stölzel F; Bug G; Bruno B; Vrhovac R; Charbonnier A; Olivieri A; Bay JO; Arroyo H; Yakoub-Agha I; Avenoso D; Neubauer A; Nguyen S; Forcade E; Brissot E; Savani B; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Sep; 57(9):1421-1427. PubMed ID: 35752739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
    Gorin NC; Labopin M; Blaise D; de Groot M; Socié G; Bourhis JH; Ciceri F; Polge E; Nagler A; Mohty M
    Cancer; 2020 Mar; 126(5):1004-1015. PubMed ID: 31774557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.
    Heinicke T; Labopin M; Polge E; Niederwieser D; Platzbecker U; Sengelov H; Choi G; Cornelissen J; Blaise D; Kuball J; van Gorkom G; Schaap N; Potter V; Paul F; Savani BN; Nagler A; Mohty M
    Bone Marrow Transplant; 2020 Apr; 55(4):729-739. PubMed ID: 31645668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
    Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation.
    Lee CJ; Labopin M; Beelen D; Finke J; Blaise D; Ganser A; Itälä-Remes M; Chevallier P; Labussière-Wallet H; Maertens J; Yakoub-Agha I; Bourhis JH; Mailhol A; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2019 Apr; 94(4):431-438. PubMed ID: 30597620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
    Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Socié G; Beauvais D; Klein S; Wagner-Drouet EM; Blaise D; Nguyen-Quoc S; Bourhis JH; Thiebaut A; Labussière-Wallet H; Charbonnier A; Berceanu A; Diez-Martin JL; Fegueux N; Esteve J; Nagler A; Mohty M
    Bone Marrow Transplant; 2021 May; 56(5):1047-1055. PubMed ID: 33235351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.